摘要
为分析丙卡特罗联合孟鲁司特对小儿支气管哮喘的疗效及对其相关血清指标及预后的影响,将180例小儿支气管患者均分为研究组及对照组(n=90),对照组给予口服孟鲁司特钠片,小于6岁患儿4mg/次,大于6岁患儿5mg/次,每晚1次。研究组在对照组的基础上口服盐酸丙卡特罗口服溶液,每次为0.25mL/kg,小于6岁患儿每日2次,大于6岁患儿每日1次,以上两组患儿治疗时间均为3个月。比较两组患者的临床疗效等差异。结果显示,研究组患者治疗的总有效率(91.11%)显著高于对照组患者(74.44%)(P<0.05)。研究组的肺功能及相关血清指标改善情况及治疗后生活质量改善程度均显著优于对照组(P<0.05)。因此可得出丙卡特罗联合孟鲁司特可有效提高支气管哮喘患儿的疗效及预后情况,值得临床大力推广应用。
To investigate the influence of clinical efficacy,serum markers and prognosis of procaterol and montelukast on children with bronchial asthma,the 180 cases of patients with children bronchial asthma will be divided into study group and control group(n=90).The control group was given montelukast sodium tablets orally,4mg/time for children younger than 6 years old and 5mg/time for children older than 6 years old,1/night.In the study group,on the basis of the control group,the oral solution of procarterol hydrochloride was taken orally,0.25 mL/kg each time,twice a day for children younger than 6 years old and once a day for children older than 6 years old,and the treatment duration of both groups was 3 months.Then the two groups were compared in terms of clinical efficacy and so on.The clinical efficacy in study group was higher than the control group(P<0.05).And the lung function and serum prognosis indexes in study group were better than the control group after treatment(P<0.05).Then the related living quality indexes in the study group were better than the control group after treatment(P<0.05).The results showed that procaterol and montelukast in the treatment of children bronchial asthma is significant,which is worthy of popularization and application.
作者
厉兰
彭贻界
王刚祚
胡绘平
LI Lan;PENG Yijie;WANG Gangzuo;HU Huiping(Department of Pediatric Surgery,Enshi 445000,Hubei,China;The Third Children Department of Enshi Central Hospital,Enshi 445000,Hubei,China)
出处
《中南医学科学杂志》
CAS
2019年第3期285-287,320,共4页
Medical Science Journal of Central South China
作者简介
通信作者:胡绘平,E-mail:1012882787@qq.com.
